N-acetyl glycoprotein
|
Basic information |
| Metabolite name | N-acetyl glycoprotein |
 | N/A |
 |
N/A |
 |
N/A |
| Synonyms | N-acetyl-glycoproteins; |
| No. of studies | 16 |
|
Basic information |
| Metabolite name | N-acetyl glycoprotein |
| N/A |
|
N/A |
|
N/A |
| Synonyms | N-acetyl-glycoproteins; |
| No. of studies | 16 |
|
Relationship between N-acetyl glycoprotein and depression (count: 16) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M014 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M014 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M014 | Type2 | CUMS + XY-A group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M017 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M030 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Up |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Up |
| Study M078 | Type1 | CORT model group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Serum | Sprague-Dawley rat | Down |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M093 | Type2 | paroxetine group vs. baseline | Serum | Human | Down |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1076 | Type2 | depression group, post Shuganjieyu treatment vs. baseline | Plasma | Human | Up |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M140 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + paroxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + SJ group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + median dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + low dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + high dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + augmentation treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Down |